Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if there is a benefit of adding Herceptin
(trastuzumab) to standard chemotherapy in this type of breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Kansas University of Kansas Medical Center